NYSE:AZN - AstraZeneca Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$39.21 +0.26 (+0.67 %)
(As of 10/21/2018 05:51 AM ET)
Previous Close$39.21
Today's Range$39.0850 - $39.51
52-Week Range$31.99 - $40.16
Volume3.57 million shs
Average Volume4.26 million shs
Market Capitalization$99.31 billion
P/E Ratio10.92
Dividend Yield2.24%
Beta0.58
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:AZN
CUSIPN/A
Phone44-20-3749-5000

Debt

Debt-to-Equity Ratio1.08
Current Ratio0.72
Quick Ratio0.54

Price-To-Earnings

Trailing P/E Ratio10.92
Forward P/E Ratio23.48
P/E Growth2.09

Sales & Book Value

Annual Sales$22.47 billion
Price / Sales4.42
Cash Flow$3.3399 per share
Price / Cash11.74
Book Value$6.57 per share
Price / Book5.97

Profitability

EPS (Most Recent Fiscal Year)$4.28
Net Income$3.00 billion
Net Margins11.98%
Return on Equity29.89%
Return on Assets7.21%

Miscellaneous

Employees61,100
Outstanding Shares2,532,900,000
Market Cap$99.31 billion

AstraZeneca (NYSE:AZN) Frequently Asked Questions

What is AstraZeneca's stock symbol?

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca announced a semiannual dividend on Friday, July 27th. Stockholders of record on Friday, August 10th will be given a dividend of $0.45 per share on Monday, September 10th. This represents a dividend yield of 2.35%. The ex-dividend date of this dividend is Thursday, August 9th. View AstraZeneca's Dividend History.

When did AstraZeneca's stock split? How did AstraZeneca's stock split work?

AstraZeneca shares split before market open on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly issued shares were issued to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

How were AstraZeneca's earnings last quarter?

AstraZeneca plc (NYSE:AZN) issued its earnings results on Thursday, July, 26th. The company reported $0.69 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.31 by $0.38. The firm earned $5.16 billion during the quarter, compared to analysts' expectations of $5.09 billion. AstraZeneca had a return on equity of 29.89% and a net margin of 11.98%. AstraZeneca's revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period in the previous year, the company earned $0.87 earnings per share. View AstraZeneca's Earnings History.

When is AstraZeneca's next earnings date?

AstraZeneca is scheduled to release their next quarterly earnings announcement on Thursday, November 8th 2018. View Earnings Estimates for AstraZeneca.

What guidance has AstraZeneca issued on next quarter's earnings?

AstraZeneca updated its FY18 earnings guidance on Thursday, July, 26th. The company provided earnings per share guidance of $3.30-3.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.41.

What price target have analysts set for AZN?

7 brokers have issued 12-month price objectives for AstraZeneca's stock. Their forecasts range from $36.70 to $42.00. On average, they anticipate AstraZeneca's share price to reach $39.4250 in the next year. This suggests a possible upside of 0.5% from the stock's current price. View Analyst Price Targets for AstraZeneca.

What is the consensus analysts' recommendation for AstraZeneca?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AstraZeneca.

Who are some of AstraZeneca's key competitors?

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the folowing people:
  • Mr. Pascal Soriot, Exec. Director & CEO (Age 59)
  • Mr. Marc Dunoyer, Exec. Director & CFO (Age 66)
  • Ms. Pam P. Cheng, Exec. Vice-Pres of Operations & Information Technology (Age 47)
  • Mr. Jefrey Pott, Gen. Counsel
  • Ms. Katarina Ageborg, Exec. VP of Sustainability & Chief Compliance Officer

Who are AstraZeneca's major shareholders?

AstraZeneca's stock is owned by many different of institutional and retail investors. Top institutional investors include Bank of Montreal Can (0.07%), Hardman Johnston Global Advisors LLC (0.05%), Aperio Group LLC (0.04%), TIAA FSB (0.01%), BB&T Corp (0.01%) and Dorsey Wright & Associates (0.01%). View Institutional Ownership Trends for AstraZeneca.

Which institutional investors are selling AstraZeneca stock?

AZN stock was sold by a variety of institutional investors in the last quarter, including TIAA FSB, Fulton Bank N.A., Essex Investment Management Co. LLC, First Bank & Trust, BB&T Corp, World Asset Management Inc, Raymond James Trust N.A. and Atria Investments LLC. View Insider Buying and Selling for AstraZeneca.

Which institutional investors are buying AstraZeneca stock?

AZN stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Dorsey Wright & Associates, Hardman Johnston Global Advisors LLC, Park National Corp OH, Aperio Group LLC, BLB&B Advisors LLC, Nisa Investment Advisors LLC and Bristol Advisors LLC. View Insider Buying and Selling for AstraZeneca.

How do I buy shares of AstraZeneca?

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately $39.21.

How big of a company is AstraZeneca?

AstraZeneca has a market capitalization of $99.31 billion and generates $22.47 billion in revenue each year. The company earns $3.00 billion in net income (profit) each year or $4.28 on an earnings per share basis. AstraZeneca employs 61,100 workers across the globe.

What is AstraZeneca's official website?

The official website for AstraZeneca is http://www.astrazeneca.com.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]


MarketBeat Community Rating for AstraZeneca (NYSE AZN)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  644 (Vote Outperform)
Underperform Votes:  961 (Vote Underperform)
Total Votes:  1,605
MarketBeat's community ratings are surveys of what our community members think about AstraZeneca and other stocks. Vote "Outperform" if you believe AZN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AZN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel